Product Manual

16 60061-7 (2021-01) Accula SARS-CoV-2 IFU
Legionella pneumonphila
No alignment found
Mycobacterium tuberculosis
No alignment found
Streptococcus pneumoniae
No alignment found
Streptococcus pyogenes
No alignment found
Bordetella pertussis
No alignment found
Mycoplasma pneumoniae
No alignment found
Pneumocystis jirovecii
No alignment found
Candida albicans
No alignment found
Pseudomonas aeruginosa
No alignment found
Staphylococcus epidermis
No alignment found
Staphylococcus salivarius
No alignment found
Exclusivity (Cross-Reactivity) Testing
The exclusivity study was performed by testing 32 potentially cross-reacting organisms with the Accula SARS-CoV-2 Test. Each organism
was diluted in a pooled negative human throat swab and nasal swab matrix and tested in triplicate. The organisms and concentrations are
shown in the table below. None of the 32 organisms cross-reacted in the Accula SARS-CoV-2 Test at the concentrations tested.